SCHEMBL10133764

SCHEMBL10133764

CC(C)(C)S(=O)(=O)NC1CCC(C(=O)Nc2cccc(Cl)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.52
GAA P10253 3/20 0.51
HTT P42858 3/20 0.51
LMNA P02545 3/20 0.51
HPGD P15428 2/20 0.51
USP2 O75604 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MALT1 Q9UDY8 1/20 0.50
KMT2A Q03164 5/20 0.49
MEN1 O00255 3/20 0.49
MGLL Q99685 4/20 0.48
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
ALPL P05186 1/20 0.47
ALPI P09923 1/20 0.47
ALPG P10696 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 1/20 0.45
EPHX1 P07099 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114352 1.00 NPY5R (0.52) NPY5RGAAHTTLMNAHPGD
SCHEMBL14424628 0.87 ALDH1A1 (0.56) NPY5RGAAHTTLMNAHPGD
SCHEMBL10113100 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL10113097 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL13203720 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL13203821 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL10114576 0.87 ALDH1A1 (0.56) NPY5RGAAHTTLMNAHPGD
SCHEMBL13203717 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL10113273 0.87 NPY5R (0.53) NPY5RGAAHTTLMNAHPGD
SCHEMBL10113327 0.86 ALDH1A1 (0.62) NPY5RGAAHTTLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPY5R 1/4885GAA 3448/4885HTT 2081/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPY5R 1/4885GAA 3316/4885HTT 1904/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPY5R 1/4885GAA 3472/4885HTT 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.